Abbvie Inc (ABBV) Stock Price, Quote & News

Company Profile

AbbVie Inc., a research-based biopharmaceutical company, engages in the research and development, manufacturing, commercializing, and sale of medicines and therapies worldwide. The company offers Skyrizi to treat autoimmune diseases; Rinvoq to treat inflammatory diseases; Imbruvica for the treatment of adult patients with blood cancers; Venclexta to treat blood cancers; Elahere to treat various cancer; and Epkinly to treat lymphoma; and Emrelis for the treatment of lung cancer. It also provides...

Industry: Drug Manufacturers - General

Sector: Healthcare

Phone: 847 932 7900

Website: www.abbvie.com

Address:

1 North Waukegan Road, North Chicago, United States

Guntz Apr. 4 at 4:21 PM

$ABBV There were no acquisitions reported this period. If the charges are because of milestones reached it could be good news. Probably won't really get clarity until ER though.

0 · Reply

PickAlpha Apr. 4 at 2:54 PM

2/3: AbbVie filed an 8-K saying Q1 2026 results will include a $744 mn pretax acquired IPR&D and milestones expense, cutting both GAAP and adjusted diluted EPS by $0.41 and reducing 2026 adjusted EPS guidance to $13.96-$14.16. | View: The 8-K introduces a clearly quantified $0.41 hit to 2026 EPS and lower guidance… $ABBV $XLV $IBB

0 · Reply

NasdaqPulse Apr. 4 at 12:08 PM

$ABBV update hitting the tape: AbbVie flagged ~$744M pre-tax hit from Q1 acquired IPR&D + milestone expenses. 👉Click to view @NasdaqPulse for timely updates amid the volatility. That’s not just a one-off—management already signaling pressure on both Q1 and full-year adjusted EPS guidance. This is the kind of accounting drag that can quietly reshape valuation expectations. Bull case: pipeline investments = future growth engine. Bear case: near-term EPS compression + guidance cuts = multiple risk. Big question now: Is this AbbVie reinvesting for long-term dominance… or just eating near-term earnings to chase pipeline upside? Watch how the market digests this Re-rate incoming… or dip buy opportunity?

0 · Reply

Guntz Apr. 4 at 10:29 AM

$ABBV Looks like more downside Monday. They filed a 8k on Friday reducing guidance

0 · Reply

UsingAGodAlgorithm Apr. 4 at 3:34 AM

$SE (-75% from short entry) We are the best on ST as far as we have seen. Check our profile We also covered these names. $ABBV $PLTR $MU $MA

2 · Reply

NasdaqPulse Apr. 3 at 2:07 PM

Pharma policy shock incoming? 👉Click to view @NasdaqPulse for timely updates amid the volatility. Reports suggest the Trump administration is preparing tariffs as high as 100% on imported branded drugs—unless companies lower prices or shift production to the U.S. 🇺🇸 Big names like Novo Nordisk ($NVO), AbbVie ($ABBV), and Merck & Co. ($MRK) could face pressure if they don’t secure exemptions or adjust their supply chains. This could be a major catalyst for: • Margin compression for global pharma • Accelerated reshoring of manufacturing • Volatility across the sector as pricing power gets tested Watch for policy updates—this could reshape pharma pricing dynamics in the U.S. market.

0 · Reply

NasdaqPulse Apr. 3 at 10:59 AM

Biotech just keeps leveling up in psoriasis 👉Click to view @NasdaqPulse for timely updates amid the volatility. Millions of patients are impacted globally, and the race is on to deliver better, faster, and more targeted solutions. The shift toward precision therapies is changing the game — higher efficacy, fewer side effects, and improved patient convenience. Big pharma isn’t sitting this one out. $ABBV and $JNJ are pushing forward with next-gen psoriasis treatments, doubling down on targeted biologics and innovation pipelines that could redefine standards of care. This space isn’t just medical — it’s a multi-billion dollar opportunity with long-term demand. Watch for clinical data, approvals, and pipeline updates… this trend is only getting stronger.

0 · Reply

SamsonStreet Apr. 3 at 12:42 AM

$ABBV AbbVie will commit to low prices

1 · Reply

biolover Apr. 2 at 10:27 PM

Any potential $ABBV deal is hanging on how much access $VKTX BL allows for vanquish data. Access will not impact trial progress. This is not about anything else at this point. Such deal could be a major boost to Abbv long term. They need it and they realize that. What I don’t know if access was given ? U guys could ask Brian !!

1 · Reply